Targeting Ero1L by Parthenolide Alleviates Cellular Senescence and Fibrosis of Localized Scleroderma by Regulating Mitochondria‐Associated Endoplasmic Reticulum Membranes Stabilization
Key claim: Parthenolide targeting of Ero1L alleviates cellular senescence and fibrosis in localized scleroderma by stabilizing mitochondria-associated endoplasmic reticulum membranes.
Abstract
Aging Cell, Volume 25, Issue 10, October 2026.
Why this matters
Localized scleroderma has lacked disease-modifying therapy, and this finding offers a mechanistic candidate — parthenolide-mediated Ero1L inhibition stabilizing mitochondria-associated ER membranes — that pulls together three threads already active in the mechanism vault (senescence, mitochondrial dysfunction, and MAM contact-site biology) into one druggable node. It also extends the parthenolide/feverfew narrative, previously tracked mainly for NF-κB and anti-cancer activity, into a senescence-and-fibrosis-of-aging frame, while leaving the biology-to-pitch gap wide: the data are preclinical scleroderma models, not healthspan.